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Key Inclusion Criteria 
• Histologically or cytologically documented solid tumor 
refractory to, or for which there is no existing, 
conventional therapy 
• Measurable disease by RECIST 1.1 
• ECOG performance status of 0 or 1  
• Age 18 years or over 
• Adequate organ function 
 
Key Exclusion Criteria 
• Concomitant investigational medical  
       product, or other anti-cancer therapy 
• Concomitant therapy with significant 
       modulators of CYP3A4 
• Pregnant, breastfeeding or of childbearing potential 
• Symptomatic CNS metastases 
 
 
Introduction 
Dose 
Level 
(mg 
BD) 
Evaluable 
(total 
treated) 
 
DLTs 
(N) 
 
G3-4 AEs 
20 3 (3) 0 elevation GGT (1, G3) 
40 3 (3) 0 nil 
80 6 (7) 1 Thrombocytopenia with 
epistaxis 
(1, G3) 
160 6 (6) 0 Anaemia (1, G3) 
240 6 (7) 4 Thrombocytopenia (2, G4),  
pancytopenia (1, G4),  
elevated amylase (1, G3), 
photosensitivity (1, G3),  
mucositis (1, G3),  
anemia (1, G3) 
Objectives 
Methods 
Results 
Primary 
• To determine the feasibility and safety of administration of single-agent AZD6738 in patients 
with solid tumours 
Secondary 
• To guide dose and schedule selection for subsequent studies of AZD6738 as a single-agent  
• To assess preliminary anti-tumour activity (by RECIST response) of AZD6738  
Exploratory 
• To conduct pharmacodynamic studies on tumour and normal tissue. 
• To assess the value of putative predictive biomarkers for response to AZD6738. 
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Demographics Tumor Types 
Median (range) 
age 
59  
(41-
80) 
SCCHN 6 
(23%) 
Median (range) 
prior systemic 
therapy 
2  
(1-4) 
Colorectal 6 
(23%) 
% Female 31 Naso-
pharyngeal 
2 (8%) 
 ECOG PS 0   Other* 12 
(46%) 
* Adrenal cortical carcinoma, peritoneal carcinoma, 
mesothelioma, small bowel adenocarcinoma, 
unknown primary, external auditory adenocarcinoma, 
eccrine adenocarcinoma, esophageal SCC (all n=1) 
Table 2: dose escalation 
Figure 1: AZD6738 concentration-time profiles 
Summary of preliminary anti-tumor responses 
Conclusions 
Further development 
Table1: baseline characteristics 
AZD67381 is a potent, selective inhibitor of ataxia  
telangiectasia and Rad3-related (ATR), a serine- 
threonine  kinase which is critical in the response to  
DNA replication stress2. 
 
Many cancers have high levels of replication stress and a poorly functional 
G1/S DNA damage checkpoint3.  This may render them more susceptible 
than normal tissues to inhibition of ATR.  Pre-clinical studies have identified 
oncogene activation4, hypoxia5, ATM loss6 and DNA damage response 
defects7,8,9 as potential sensitizers to ATR inhibition, as well as sensitization to 
ionizing radiation10. 
We report the results of the monotherapy dose-escalation phase of the 
PATRIOT study of AZD6738, an orally active ATR inhibitor in patients with 
advanced solid tumors, the endpoints of which were MTD, safety, 
tolerability, pharmacokinetics (PK) and preliminary efficacy. 
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Figure 7: duration on study 
Adverse Event Number 
(%) G1-4 
Number 
(%) G3-4 
Fatigue 9 (35%) 0 
Anemia 7 (23%) 3 (12%) 
Nausea 4 (15%) 0 
Thrombocytopenia 5 (19%) 4 (16%) 
Anorexia 3 (12%) 0 
Dysgeusia 3 (12%) 0 
Vomiting 2 (8%) 0 
Rash 2 (8%) 0 
N=1 AEs: dyspnoea G1, nail changes, insomnia 
G2, tinnitus G1, stomatitis G2 
Table 3: Treatment-related AEs affecting ≥2 
participants (probable or definite) 
Figure 2: pS345Chk1 IHC 
baseline day 15 
Figure 4: Recurrent SCC head and neck 
26 patients were enrolled between July 
2014 and July 2016 in a 3+3 design.  
Baseline characteristics are shown in 
table 1. 
Patients received continuous twice daily 
(BD) dosing.   
Preliminary PK analysis  
AZD6738 is rapidly orally absorbed 
(median tmax 1-5 h), with mean terminal 
elimination half-life 6.1-12.1 h. Following 
single dosing, AZD6738 exposure 
Expansion cohorts have 
been initiated at 160mg BD, 
exploring a number of 
alternative treatment 
schedules designed to 
offset cumulative toxicity 
and test efficacy of 
AZD6738 monotherapy and 
the presence of high 
replication stress, DNA 
damage response 
deficiencies or ATM loss.  A 
parallel part of the study is 
investigating AZD6738 in 
combination with palliative 
radiotherapy. 
 
Two RECIST partial responses were observed in patients with SCCHN (fig. 4 A, 
B) and nasopharyngeal carcinoma (fig. 5 A, B), one confirmed. 
 
A B 
Figure 5: Recurrent nasopharyngeal carcinoma 
A B 
(defined as definitely or probably related by the investigator) are shown in 
table 3. 
Median duration taking AZD6738 was 101 days, range 30-281 days 
(evaluable patients only).  
One patient remains on treatment, three patients discontinued due to 
treatment-related toxicities. 
Figure 6: best responses 
62 year old female, recurrent SCC oral cavity. 
AZD6738 40 mg BD 
Prior treatment:  cisplatin-5FU (best response: SD); 
 nivolumab (best response: SD). 
Biomarker:  Wee1 mutation with predicted 
 functional impact.  40% Ki67 
 positivity 
Response: PR in target lesions, new lesion 
 on confirmation CT 
 
40 year-old male, recurrent undifferentiated 
nasopharygeal carcinoma 
AZD6738 240 mg BD 
Prior treatment:  cisplatin-5FU (best response: SD); 
 vaccination study; durvalumab 
 (best response: SD) 
Biomarker:  NRAS oncogenic mutation, 90% 
 Ki67 positivity 
Response: confirmed PR 
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Figure 8: overall design of the PATRIOT study 
The maximum tolerated dose was 160 mg BD. 
Dose-limiting toxicities were thrombocytopenia, pancytopenia and 
elevated amylase (table 2).  All resolved on interruption of AZD6738. 
Other adverse events related to AZD6738   
Figure 3 ATR activates Chk1 Preliminary evidence of 
target engagement 
Paired biopsies were taken 
in a limited number of 
patients. Fig. 2 shows 
reduction in Chk1 
phosphorylation at Ser-345 
indicative of reduced ATR 
activity at 40 and 240 mg 
BD. 
. 
 
• AZD6738 is tolerated at 160 mg BD as continuous monotherapy.   
• AZD6738 pharmacokinetics are approximately dose-proportional. 
• Preliminary evidence of target engagement has been observed. 
• Preliminary data suggest that monotherapy ATR inhibition may be 
associated with objective responses or disease stabilisation. 
Expansion cohorts will further examine these observations: 
• Tumor responses in patients with defective DNA damage 
response; 
• Tumor responses in lesions with high Ki67. 
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increased approximately proportionally with dose between 80 – 240 mg. The 
increase between 20 mg and 40 mg appeared to be slightly more than 
dose proportional (fig. 1). 
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